ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

Takara Bio to mass-produce COVID-19 vaccine candidate

Japanese biotech company hopes to supply 200,000 people this year

Takara Bio says it has a DNA vaccine that can help a person's immune system successfully attack the new coronavirus.   © Takara Bio

TOKYO -- Japanese biotech company Takara Bio plans to mass produce novel coronavirus vaccinations as early as this year, President and CEO Koichi Nakao told Nikkei in an interview.

Takara partnered with bio company AnGes and Osaka University to develop the DNA vaccine. It will start clinical trials in the summer. If Japan's health ministry approves a production and sales license this fall, the company would be ready to supply vaccines to 200,000 people this year.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more